Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The NeoFox study is currently in a key phase, when the recruitment of patients must intensify to enable the analysis of data. It is thus essential to ensure the continuity of the management over the forthcoming period. Peter Morsing will remain in an advisory role during his period of notice, until January 2021.
Anders has served as CEO for a number of companies in the biotechnology and finance industries. Over the course of about ten years, until November 2019, Anders was the CEO of Isofol Medical AB (publ), leading the company from academic research to a global phase III program for treatment of colorectal cancer. He further prepared the company for the commercialization and out-licensing of its drug candidate. Anders has extensive experience of managing business development, clinical projects and regulatory processes. As the CEO of listed companies on Nasdaq First North Premier, Anders also is well experienced with the requirements and obligations of a listed company.
"As the new CEO, I look forward to participate in the continued development of the drug candidate Foxy-5 and to improve the treatment of patients suffering from colorectal cancer. The objective of Foxy-5 is to avoid the spread of cancer cells before and after surgery and thereby reduce the risk of recurrence significantly. My primary challenge as the CEO of WntResearch is to ensure the inclusion of patients in the Company's ongoing phase II study and to continue to build the Company's clinical development plan and regulatory strategy, which will be instrumental in the future registration and commercialization of Foxy-5," says Anders Rabbe.
"The Board of Directors of WntResearch would like to express its sincere thanks to Peter Morsing for his efforts, which have brought the company to the current stage. We welcome Anders and look forward to working with him in the important activities we are facing. The board is working continuously to strengthen the organization and to build the team that WntResearch needs, in the short and the longer term, to achieve significant milestones," says Gudrun Anstrén, Chair of the Board.
For more information, please contact:
Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.com
Telephone: +46 727 200711
This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on October 1, 2020.
About WntResearch
WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The Company focuses on WNT5A, a protein that suppresses the metastatic process in the body; the vision is for cancer patients to no longer have to endure metastasis. Today, one in every three people will develop cancer during their lifetimes, and 90 percent of all cancer-related deaths are caused by metastases. Even though cancer treatment has become more effective, there are no effective methods to prevent the formation of metastasis. The drug candidate Foxy-5 mimics WNT5A' s ability to reduce the mobility and thus the spread of cancer cells. Foxy-5 has demonstrated a good safety profile with few adverse effects in two clinical phase I studies. An ongoing clinical phase II study is currently being conducted on patients with colon cancer with the Company's drug candidate Foxy-5. According to the Company's assessment, Foxy-5 is the only drug candidate of its kind, with a unique mode of action in an area where other drug or treatment options are lacking. WntResearch's share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com